Skip to main content
SpringerLink
Log in

Novel inhaler reduces costs and environmental burden

  • Non-clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. The study was funded by Boehringer Ingelheim.

Reference

  • Ortsater G, et al. Incorporating the Environmental Impact into a Budget Impact Analysis: The Example of Adopting RESPIMAT Re-usable Inhaler. Applied Health Economics and Health Policy : 6 Dec 2019. Available from: URL: https://doi.org/10.1007/s40258-019-00540-0

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Novel inhaler reduces costs and environmental burden. PharmacoEcon Outcomes News 844, 26 (2020). https://doi.org/10.1007/s40274-020-6489-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-020-6489-y

Search

Navigation